The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents

Table 2

Changes in overactive bladder symptoms by previous anticholinergic agent and by gender.

Variables	Overactive bladder symptom scores
	Baseline	4 weeks	12 weeks	P-value^(2)
Solifenacin (𝑛=27)	9.4±2.5^(1)	7.2±3.9 **	6.5±3.9 **	𝑃=0.31
Tolterodine (𝑛=10)	8.4±1.4	4.7±1.7 **	5.9±2.5 *
Imidafenacin (𝑛=15)	8.7±2.1	5.4±2.2 **	6.1±2.8 **
Male (𝑛=21)	8.5±1.9	6.9±3.2 **	6.4±2.9 **	𝑃<0.01
Female (𝑛=31)	9.4±2.4	5.7±3.3 **	6.1±3.6 **

⁽¹⁾Mean ± standard deviation.
⁽²⁾Comparison among groups (combined analysis model).
* 𝑃<0.01, **𝑃<0.001 (versus baseline, paired t-test).